1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,280 | 0,382 | 11:22 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.01. | Scandinavian ChemoTech AB: New Year's Letter to Shareholders in Scandinavian ChemoTech - Reflecting on 2025 | 106 | GlobeNewswire (Europe) | Dear Shareholders,
As we enter 2026, I would like to thank you for your continued trust and support of Scandinavian ChemoTech. The past year, 2025, has been an important one for the Company, a year... ► Artikel lesen | |
| 04.11.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech AB (publ) publishes Interim Report Q3 2025 | 112 | GlobeNewswire (Europe) | The report is attached to this press release and can also be downloaded from the company's website.
July - September 2025 ... ► Artikel lesen | |
| 17.10.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech's Animal Care Surpasses 3,000 Treatments Performed Worldwide | 144 | GlobeNewswire (Europe) | Scandinavian ChemoTech's Animal Care, a pioneer in making oncology care more compassionate and human for animals, proudly announces another achievement: over 3,000 treatments have now been performed... ► Artikel lesen | |
| SCANDINAVIAN CHEMOTECH Aktie jetzt für 0€ handeln | |||||
| 01.10.25 | Scandinavian ChemoTech AB: ChemoTech's Animal Care Reports Strong Q3 Sales, Surpassing Expectations Despite Seasonal Slowdown | 149 | GlobeNewswire (Europe) | Scandinavian ChemoTech AB's Animal Care division is proud to announce another strong quarter, generating sales of USD 340,000 in Q3 2025. This result is within USD 50,000 of the company's record-breaking... ► Artikel lesen | |
| 26.09.25 | Scandinavian ChemoTech AB: ChemoTech's Animal Care Successfully Enters Swiss Market as Part of DACH Expansion | 481 | GlobeNewswire (Europe) | Scandinavian ChemoTech and its subsidiary VQ Animal Care Inc. is pleased to announce that it has officially started marketing vetIQure, its Tumor Specific Electroporation (TSE) technology in Switzerland.... ► Artikel lesen | |
| 19.09.25 | Scandinavian ChemoTech Hosts Successful TSE Best Practice Sharing Session with Dr. Brendan Boostrom | 1 | Cision News | ||
| 10.09.25 | Scandinavian ChemoTech AB: ChemoTech Expands in Illinois as 8th Clinic within Major U.S. Veterinary Group Adopts TSE Technology | 123 | GlobeNewswire (Europe) | Scandinavian ChemoTech AB today announced that its veterinary subsidiary, VQ Animal Care Inc., has secured a new partnership in Illinois. With this latest order, the eighth clinic within one of the... ► Artikel lesen | |
| 25.08.25 | Scandinavian ChemoTech Expands in Florida with Fourth Veterinary Oncology Clinic Partnership | 2 | Cision News | ||
| 20.08.25 | Scandinavian ChemoTech's Animal Care Surpasses 2,500 Treatment-kits sold Worldwide | 2 | Cision News | ||
| 12.08.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech AB (publ) publishes Interim Report Q2 2025 | 170 | GlobeNewswire (Europe) | Second quarter sales reached 3,841 KSEK, which is the best quarter so far. All sales originated from Animal Care. The report is attached to this press release and can also be downloaded from the company's... ► Artikel lesen | |
| 29.07.25 | Scandinavian ChemoTech Welcomes Strategic Investors from the announce Directed Share Issue to Accelerate Global Growth | 2 | Cision News | ||
| 27.07.25 | Scandinavian ChemoTech AB (publ) carries out a directed share issue and receives approximately 4.85 MSEK | 2 | Cision News | ||
| 25.07.25 | (RETRANS) Scandinavian ChemoTech's TSE Treatment Shows High Response Rate in Veterinary Cancer Study - Validated by Approved PhD Dissertation | 1 | Cision News | ||
| 01.07.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech's Animal Care Division Achieves Record-Breaking Sales in Q2 2025 | 179 | GlobeNewswire (Europe) | Scandinavian ChemoTech AB's Animal Care division proudly announces record-breaking sales in the second quarter of 2025. With continued momentum from a strong start to the quarter, the team achieved... ► Artikel lesen | |
| 06.05.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech AB (publ) publishes Interim Report Q1 2025 | 177 | GlobeNewswire (Europe) | Scandinavian ChemoTech AB (publ) hereby publishes the Interim Report for Q1 2025.
First-quarter sales reached 2 472 KSEK, which is the best quarter so far. All sales originated from Animal Care.
First... ► Artikel lesen | |
| 04.03.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech AB (publ) publishes Year-End Report January - December 2024 | 188 | GlobeNewswire (Europe) | Scandinavian ChemoTech AB (publ) hereby publishes the Year-End Report for 2024.
Fourth-quarter sales reached 2 041 KSEK, which is the best quarter in 2024. Total annual sales amounted to 6 566 KSEK-entirely... ► Artikel lesen | |
| 30.01.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech Restructures Loans and Doubles the Duration to 12 Months | 239 | GlobeNewswire (Europe) | ChemoTech is pleased to announce the signing of new restructured loan agreements to replace its previous short-term bridge financing. The new agreements include a 2.4 MSEK loan from two external investors... ► Artikel lesen | |
| 24.01.25 | Scandinavian ChemoTech AB: Scandinavian ChemoTech's Animal Care operations showed positive cashflow for 2024 in separate reporting | 285 | GlobeNewswire (Europe) | Scandinavian ChemoTech is pleased to announce that our Animal Care operations would already be showing a positive cash flow if we reported our business areas separately. This underscores the importance... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INVO FERTILITY | 2,385 | 0,00 % | INVO Fertility, Inc.: INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy | SARASOTA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation... ► Artikel lesen | |
| GENEDX | 99,54 | 0,00 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PROGYNY | 25,390 | 0,00 % | Forecasting The Future: 6 Analyst Projections For Progyny | ||
| HEARTFLOW | 34,190 | 0,00 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 38,730 | 0,00 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| FRESENIUS | 46,880 | -0,51 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Fresenius mit einem Kursziel von 53,60 Euro auf "Overweight" belassen. Der Medizinkonzern wolle an der aktuellen Struktur festhalten... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 36,260 | +0,78 % | AKTIE IM FOKUS: FMC schließen sich Davita-Schwäche an - Grippesaison in USA | FRANKFURT (dpa-AFX Broker) - Die Aktien von FMC sind am Mittwoch unter 37 Euro und damit auf das tiefste Niveau seit Herbst 2024 gefallen. Dabei verloren die Papiere des Dialysekonzerns 6 Prozent.... ► Artikel lesen | |
| BILLIONTOONE | 85,95 | -3,13 % | BillionToOne und Epic: Diagnostiktests werden in Patientenakten integriert | ||
| PROCEPT BIOROBOTICS | 30,300 | 0,00 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 22,730 | 0,00 % | Alignment Healthcare USA, LLC: Alignment Health Appoints Adnan Mansour as Chief Digital Officer to Accelerate AI-Driven Growth and Technology Leadership | ||
| SIEMENS HEALTHINEERS | 44,130 | -0,88 % | ANALYSE-FLASH: UBS hebt Ziel für Siemens Healthineers auf 51 Euro - 'Neutral' | ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat das Kursziel für Siemens Healthineers von 50 auf 51 Euro angehoben, aber die Einstufung auf "Neutral" belassen. Die Aktien der Bayern seien... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 35,120 | -0,96 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Carl Zeiss Meditec vor Zahlen mit einem Kursziel von 50,55 Euro auf "Outperform" belassen. Das erste Quartal... ► Artikel lesen | |
| BETA BIONICS | 18,435 | 0,00 % | Beta Bionics, Inc.: Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 | ||
| AIRSCULPT TECHNOLOGIES | 2,775 | 0,00 % | Airsculpt Technologies, Inc.: AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board | MIAMI BEACH, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 9,130 | -0,98 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Announces Updated Full Year 2025 and Initial Full Year 2026 Guidance | ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient... ► Artikel lesen |
Das Unternehmen SCANDINAVIAN CHEMOTECH AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,280 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCANDINAVIAN CHEMOTECH AB finden Sie auf Wallstreet Online.